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METHODS
Data source
The US Optum Research Database (Optum) comprises data for health insurance beneficiaries enrolled in commercial UnitedHealth Group-affiliated health plans. The database includes data for approximately 14 million patients on a yearly basis and 60 million patients in total,
representing a large geographically diverse population across the US. All these databases include comprehensive information on demographic and enrollment records, hospital admissions, pharmacy dispensing claims data from outpatient clinics, and vital status.
The RER database does not contain information on outpatient resource utilization and days supply of medications for each pharmacy dispensing. Data from each dataset could be linked via anonymized unique patient identifiers within individual databases. In general, these five databases cover widely geographically, socioeconomically, and clinically diverse individuals, which facilitates the generalizability of this study.
Definition of continuous enrollment
For Optum, PACE, and PAAD databases, continuous enrollment was operationally defined as having no insurance coverage gap of greater than 30 days during the 180 days before the index hospitalization admission. For the RER database, continuous enrollment was defined as having an at least 180-day residency in Emilia-Romagna. For the Taiwan NHI database, continuous enrollment was defined as having >=1 hospital admission or outpatient visit during this period.
Study population and study drugs
ACS hospitalization was defined as an inpatient stay for acute myocardial (MI) or unstable angina using International Classification of Diseases, 9th Revision, Clinical modification (ICD-9-CM) codes 410.x0, 410.x1, 411.xx in any position on an inpatient claim. The COPD diagnosis was defined as any inpatient or outpatient ICD-9-CM codes 491.xx, 492.xx, or 496.xx in any position (except for the RER database, in which information was available only from inpatient diagnosis files).
Outcomes and follow-up
CV hospitalizations were defined as first hospitalization for a composite CV event, including acute MI, unstable angina, and congestive heart failure (CHF) 410.x1, 411.xx, 428 .xx based on the primary diagnosis) following the index date. COPD hospitalization was the first hospitalized event (ICD-9-CM codes 491.xx, 492.xx, 496.xx, based on the primary diagnosis) following the index date. Specific for Taiwan NHI  database  68023A,68023B,  68024A,68024B,68025A,  68025B,83064A1, 97901K, 97902A,  97903B, 97906K, 97907A, 97908B,  97911K, 97912A, 97913B,97916K,  97917A, 97918B, 33076A, 33076B,  33077A, 33077B, 33078A, 33078B,  97511K, 97512A, 97513B, 97516K,  97517A, 97518B, 97521K, 428.xx, 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13 531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 578 293.83, 296.2x, 296.3x, 296.82, 296.90, 298.0, 300.4, 309.0, 309.1, 309.28, 311, 300.0x-300.3x, 300.5x-300.9x, 295.xx, 297.xx-299.xx, 290.8, 290.9, 780.1, 296.0x, 296.1x, 296 .4x-296.9x Abbreviations: ACS, acute coronary syndromes; BBs, β-blockers; CABG, Coronary Artery Bypass Graft Surgery; CHF, Congestive heart failure; COPD, chronic obstructive pulmonary disease; DHP CCBs, dihydropyridine calcium channel blockers; IHD, Ischemia heart disease; MI, myocardial infarction; NHI, national health insurance; PTCA, percutaneous transluminal coronary angioplasty; Peripheral vascular disease, PVD; TIA, Transient ischemic attack. a Comorbidities were measured based on any diagnosis positions in inpatient and outpatient diagnosis files. b Cardiovascular episodes included: MI, coronary revascularization (PTCA, stent, CABG), hemorrhagic stroke, ischemic stroke, TIA, hypertension, angina, IHD, cardiac dysrhythmia, atrial fibrillation, CHF, cerebrovascular disease, and PVD. c Respiratory -related episodes included COPD, asthma, pneumonia, influenza, and acute bronchitis. Inhaled long-acting bronchodilators  R03AC12, R03AC13, R03AC16, R03AC18, R03AK06,  R03AK07, R03BB04  ICS  R03BA, R03AK06, R03AK07  Oral corticosteroids  H02AB, H02BX  Oral bronchodilators  R03CC02, R03CC03, R03CC04, R03CC05, R03CC08,  R03CC09, R03CC12, R03CC13, R03CC91  R03DA04, R03DA05  Antibiotics  J01  Histamine 2 antagonists / PPIs  A02BA, A02BC  COX-2 selective NSAIDs  M01AH  COX-2 nonselective NSAIDs  M01AA, M01AB, M01AC, M01AE, M01AG,  M01AX  Anti-epileptics  N03  Anti-psychiatric drugs N06A, N05B, N05C, N05A Abbreviations: ACEIs, angiotensin converting enzyme inhibitors; ACS, acute coronary syndromes; ARBs, angiotensin Ⅱ receptor blockers; BBs, β-blockers; Cox, cyclooxygenase; DHP CCBs, dihydropyridine calcium channel blockers; ICS, inhaled corticosteroids; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors. Pulmonary-related episodes included COPD, asthma, pneumonia, influenza, and acute bronchitis. Abbreviations: BBs, β-blockers; CHF, congestive heart failure; CV, cardiovascular; DHP CCBs, dihydropyridine calcium channel blockers; MI, myocardial infarction; NHI, National Health Insurance; PAAD, Pharmacy Assistance for the Aged and Disabled; PACE, Pharmacy Assistance Contract for the Elderly; PS, propensity score; RER, Emilia-Romagna Region.
a All the cases were in the cardioselective BB unmatched group (n=21 for the analysis that considered first exposure carried forward and n=10 for as the treated analysis). BBs indicate β-blockers; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DHP CCBs, dihydropyridine calcium channel blockers.
*based on the analysis that considered first exposure carried forward.
